Adrenoceptors and serotonin receptor function: Relevance to antidepressant mechanisms of action

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 4, 1996, Pages 4-8

  Potter, William Z ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR;

DEPRESSION; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; REVIEW; SEROTONIN RELEASE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; AUTORECEPTORS; DEPRESSIVE DISORDER; HUMANS; HYDROXYINDOLEACETIC ACID; METHOXYHYDROXYPHENYLGLYCOL; MODELS, NEUROLOGICAL; NOREPINEPHRINE; RATS; RECEPTORS, ADRENERGIC; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION;

EID: 0029885576     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Danish University Antidepressant Group. Cilalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-138
2. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
3. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology 1994;8:238-249
4. Potter WZ, Scheinin M, Golden RM, et al. Selective antidepressants lack specificity on norepinephrine and serotonin metabolites in cerebrospinal fluid. Arch Gen Psychiatry 1985;42:1171-1177
5. Risby ED, Hsiao JK, Sunderland T, et al. The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio. Clin Pharmacol Ther 1987;42(5):547-554
6. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994;10(1):18-46
7. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-418
8. Delgado PL, Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29(3): 389-396
9. Delgado PL, Price LH, Miller HL, et al. Serotonin and the neurology of depression: effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994;51:865-874
10. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-226
11. Maj J, Klimek VJ, Nowak G. Antidepressant drugs given repeatedly increase binding to alpha-1-adrenoceptors in the rat cortex. Eur J Pharmacol 1985;119:113-116
12. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993;15: 243-245
13. Rutter JJ, Gundlah C, Auerbach SB. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 1994;171:183-186
14. Engleman EA, Perry KW, Mayle DA, et al. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 1995;12:287-296
15. Blier P, Galsin A-M, Langer SZ. Interaction between serotonin uptake inhibitors and alpha-2 adrenergic heteroreceptors in the rat hypothalamus. J Pharmacol Exp Ther 1990;254(1):236-254
16. Rudorfer MV, Risby ED, Hsiao JK. Disparate biochemical actions of electroconvulsive therapy and antidepressant drugs. Convulsive Ther 1988;4: 133-140
17. Manji HK, Hsiao JK, Risby ED. ECT treatment does not enhance neuroendocrine responses to serotonergic challenge. Journal of Psychopharmacology 1992;6(4):501-508
18. Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 1980;19:355
19. 1-Adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 1994;261:59-65
20. Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatment: an in vivo electrophysiological study in the rat. Neuropsychopharmacology 1991;5:219-229
21. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-251
22. Manier DH, Gillespie DD, Sanders-Bush E, et al. The serotonin/ noradrenaline link in brain, I: role of noradrenaline and serotonin in the regulation of density and function of beta adrenoceptors and its alteration by desipramine. Naunyn Schmiedebergs Arch Pharmacol 1987; 355:109-114
23. Asberg M, Bertüsson L, Martensson B, et al. CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 1984;69:201-219
24. Hsiao JK, Colison J, Bartko JJ, et al. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry 1993;50:606-614
25. Agren H, Mefford IN, Rudorfer MV. Interacting neurotransmitter systems: a non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiatr Res 1986;20:175-193
26. Potter WZ, Manji HK. Dopaminergic drugs and systems in refractory depression. In: Nolen WZ, Zohar J, Roose SP, et al, eds. Refractory Depression: Current Strategies and Future Directions, vol 21. New York, NY: John Wiley & Sons; 1994:214-227
27. Meltzer HY, Maes M. Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin response in normal men. Biol Psychiatry 1995;38:310-318
28. 1A receptor activation by flesinoxan in humans: body temperature and neuroendocrine responses. Neuropsychopharmacology 1995;13:93-104
29. Elliot HL, Jones R, Vincent J, et al. The alpha adrenoceptor antagonist properties of idazoxan in normal subjects. Clin Pharmacol Ther 1984;36: 190-196
30. Glue P, Wilson S, Lawson C, et al. Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects. J Psychopharmacol 1991;5:394-401
31. Van Veldhuizen MJA, Feenstra MGP, Heinsbroek RPW, et al. In vivo microdialysis of notadrenaline overflow: effects of α-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves. Br J Pharmacol 1993;109(3):655-660
32. Abercrombie ED, Keller RW, Zigmond JM. Characterization of hippocampal norepinephrine release as measured by microdialysis perfusion: pharmacological and behavioral studies. Neuroscience 1988; 27(3):897-904
33. 2-adrenergic receptor antagonist ethoxyidazoxan in healthy volunteers. Clin Pharmacol Ther 1994;56:420-429
34. Pickar D, Owen RR, Litman RE, et al. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49:345-353
35. Glue P, Wilson S, Campling G, et al. Atpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: effects of acute and chronic idazoxan. Psychoneuroendocrinology 1992;17:261-266
36. Pinder RM, Fink M, Mianserin. Mod Probl Pharmacopsychiatry 1983; 18:70-101
37. 2-adrenoceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995;10(suppl):S107-S118
38. de Boer T, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-AZA-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology 1988;27(4):399-408
39. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(suppl 4):19-25
40. Feuerstein TJ, Mutschler A, Lupp A, et al. Endogenous noradrenaline activates alpha-2-adrenoceptors on serotonergic nerve endings in human and rat neocortex. J Neurochem 1993;61:474-480
41. Murphy DL, Mitchell PB, Potter WZ. Novel pharmacological approaches to the treatment of depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress, New York, NY: Raven Press; 1995;1143-1153
42. 3H]dopamine release from rat nucleus accumbens slices. Neurochem Res 1993;18:285-289
43. Beani L,Tanganelli S, Antonelli T, et al. Noradrenergic modulation of cortical acetylcholine release is both direct and gamma-aminobutyric acidmediated. J Pharmacol Exp Ther 1986;236:230-236
44. Vizi ES. Modulation of cortical release of acetylcholine by noradrenaline released from nerves arising from the rat locus coeruleus. Neuroscience 1980;5:2139-2144
45. 2-adrenoceptor antagonists in volunteers and depressed patients. In: Montgomery SA, Corn TH, eds. Psychopharmacology of Depression: British Association for Psychopharmacology Monograph, No. 13. New York, NY: Oxford University Press; 1994:102-128